Advertisement
Screener

INNOVIVA, INC. (INVA) Interest Expense

2.8 / 5 stars · 68/120 Roast Me

INNOVIVA, INC. Interest Expense

INNOVIVA, INC. (INVA) reported Interest Expense of $5.47 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.

Financial Statements › Expense Statement

us-gaap:InterestExpense · last filed 2026-08-05

  • INNOVIVA, INC. interest expense for the quarter ending 2026-06-30 was $5.47M, a 17.35% increase year-over-year.
  • INNOVIVA, INC. interest expense for the quarter ending 2026-03-31 was $5.44M, a 15.41% increase year-over-year.
  • INNOVIVA, INC. interest expense for the quarter ending 2025-12-31 was $3.31M, a 30.32% decline year-over-year.
  • INNOVIVA, INC. interest expense for the quarter ending 2025-09-30 was $4.01M, a 30.86% decline year-over-year.
  • INNOVIVA, INC. interest expense for fiscal 2025 was $16.70M, a 24.81% decline from fiscal 2024.
  • INNOVIVA, INC. interest expense for fiscal 2024 was $22.21M, a 15.93% increase from fiscal 2023.
  • INNOVIVA, INC. interest expense for fiscal 2023 was $19.16M, a 21.33% increase from fiscal 2022.
  • INNOVIVA, INC. interest expense for fiscal 2022 was $15.79M, a 17.21% decline from fiscal 2021.
Period endInterest Expense 3 monthInterest Expense 3 month as first filedInterest Expense 6 monthInterest Expense 9 monthInterest Expense 12 month
2026-06-30$5.47M
10-Q · filed 2026-08-05
$10.91M
10-Q · filed 2026-08-05
$14.22M
derived: sum of 3 quarters · filed 2026-08-05
$18.23M
derived: sum of 4 quarters · filed 2026-08-05
2026-03-31$5.44M
10-Q · filed 2026-05-06
$8.75M
derived: sum of 2 quarters · filed 2026-05-06
$12.76M
derived: sum of 3 quarters · filed 2026-05-06
$17.42M
derived: sum of 4 quarters · filed 2026-08-05
2025-12-31$3.31M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25
$7.32M
derived: sum of 2 quarters · filed 2026-02-25
$11.99M
derived: sum of 3 quarters · filed 2026-08-05
$16.70M
10-K · filed 2026-02-25
2025-09-30$4.01M
10-Q · filed 2025-11-05
$8.68M
derived: sum of 2 quarters · filed 2026-08-05
$13.39M
10-Q · filed 2025-11-05
$18.14M
derived: sum of 4 quarters · filed 2026-08-05
2025-06-30$4.66M
10-Q · filed 2026-08-05
$9.37M
10-Q · filed 2026-08-05
$14.12M
derived: sum of 3 quarters · filed 2026-08-05
$19.93M
derived: sum of 4 quarters · filed 2026-08-05
2025-03-31$4.71M
10-Q · filed 2026-05-06
$9.46M
derived: sum of 2 quarters · filed 2026-05-06
$15.27M
derived: sum of 3 quarters · filed 2026-05-06
$21.07M
derived: sum of 4 quarters · filed 2026-05-06
2024-12-31$4.75M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25
$10.56M
derived: sum of 2 quarters · filed 2026-02-25
$16.36M
derived: sum of 3 quarters · filed 2026-02-25
$22.21M
10-K · filed 2026-02-25
2024-09-30$5.81M
10-Q · filed 2025-11-05
$11.61M
derived: sum of 2 quarters · filed 2025-11-05
$17.46M
10-Q · filed 2025-11-05
$23.41M
derived: sum of 4 quarters · filed 2026-02-25
2024-06-30$5.80M
10-Q · filed 2025-08-06
$11.65M
10-Q · filed 2025-08-06
$17.61M
derived: sum of 3 quarters · filed 2026-02-25
$22.00M
derived: sum of 4 quarters · filed 2026-02-25
2024-03-31$5.85M
10-Q · filed 2025-05-07
$11.80M
derived: sum of 2 quarters · filed 2026-02-25
$16.20M
derived: sum of 3 quarters · filed 2026-02-25
$20.58M
derived: sum of 4 quarters · filed 2026-02-25
2023-12-31$5.95M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25
$10.35M
derived: sum of 2 quarters · filed 2026-02-25
$14.73M
derived: sum of 3 quarters · filed 2026-02-25
$19.16M
10-K · filed 2026-02-25
2023-09-30$4.40M
10-Q · filed 2024-11-06
$8.78M
derived: sum of 2 quarters · filed 2024-11-06
$13.21M
10-Q · filed 2024-11-06
$17.23M
derived: sum of 4 quarters · filed 2025-02-26
2023-06-30$4.38M
10-Q · filed 2024-07-31
$8.81M
10-Q · filed 2024-07-31
$12.84M
derived: sum of 3 quarters · filed 2025-02-26
$17.93M
derived: sum of 4 quarters · filed 2025-02-26
2023-03-31$4.43M
10-Q · filed 2024-05-08
$8.46M
derived: sum of 2 quarters · filed 2025-02-26
$13.55M
derived: sum of 3 quarters · filed 2025-02-26
$17.21M
derived: sum of 4 quarters · filed 2025-02-26
2022-12-31$4.03M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26
$9.12M
derived: sum of 2 quarters · filed 2025-02-26
$12.78M
derived: sum of 3 quarters · filed 2025-02-26
$15.79M
10-K · filed 2025-02-26
2022-09-30$5.10M
10-Q · filed 2023-11-01
$8.75M
derived: sum of 2 quarters · filed 2023-11-01
$11.76M
10-Q · filed 2023-11-01
$16.60M
derived: sum of 4 quarters · filed 2024-03-05
2022-06-30$3.65M
10-Q · filed 2023-08-02
$6.67M
10-Q · filed 2023-08-02
$11.51M
derived: sum of 3 quarters · filed 2024-03-05
$16.30M
derived: sum of 4 quarters · filed 2024-03-05
2022-03-31$3.01M
10-Q · filed 2023-05-09
$7.85M
derived: sum of 2 quarters · filed 2024-03-05
$12.64M
derived: sum of 3 quarters · filed 2024-03-05
$17.39M
derived: sum of 4 quarters · filed 2024-03-05
2021-12-31$4.84M
derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-03-05
$9.63M
derived: sum of 2 quarters · filed 2024-03-05
$14.38M
derived: sum of 3 quarters · filed 2024-03-05
$19.07M
10-K/A · filed 2024-03-05
2021-09-30$4.79M
10-Q · filed 2022-11-09
$9.54M
derived: sum of 2 quarters · filed 2022-11-09
$14.23M
10-Q · filed 2022-11-09
$18.88M
derived: sum of 4 quarters · filed 2023-02-28
2021-06-30$4.75M
10-Q · filed 2022-07-27
$9.44M
10-Q · filed 2022-07-27
$14.09M
derived: sum of 3 quarters · filed 2023-02-28
$18.69M
derived: sum of 4 quarters · filed 2023-02-28
2021-03-31$4.69M
10-Q · filed 2022-05-05
$9.35M
derived: sum of 2 quarters · filed 2023-02-28
$13.95M
derived: sum of 3 quarters · filed 2023-02-28
$18.51M
derived: sum of 4 quarters · filed 2023-02-28
2020-12-31$4.65M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28
$9.25M
derived: sum of 2 quarters · filed 2023-02-28
$13.81M
derived: sum of 3 quarters · filed 2023-02-28
$18.33M
10-K · filed 2023-02-28
2020-09-30$4.60M
10-Q · filed 2021-10-27
$9.16M
derived: sum of 2 quarters · filed 2021-10-27
$13.68M
10-Q · filed 2021-10-27
$18.37M
derived: sum of 4 quarters · filed 2022-03-17
2020-06-30$4.56M
10-Q · filed 2021-07-29
$9.08M
10-Q · filed 2021-07-29
$13.77M
derived: sum of 3 quarters · filed 2022-03-17
$18.46M
derived: sum of 4 quarters · filed 2022-03-17
2020-03-31$4.52M
10-Q · filed 2021-04-28
$9.21M
derived: sum of 2 quarters · filed 2022-03-17
$13.90M
derived: sum of 3 quarters · filed 2022-03-17
$18.56M
derived: sum of 4 quarters · filed 2022-03-17
2019-12-31$4.69M
derived: 10-K/A 12 month − 10-Q 9 month · filed 2022-03-17
$9.38M
derived: sum of 2 quarters · filed 2022-03-17
$14.04M
derived: sum of 3 quarters · filed 2022-03-17
$18.66M
10-K/A · filed 2022-03-17
2019-09-30$4.69M
10-Q · filed 2020-10-28
$9.35M
derived: sum of 2 quarters · filed 2020-10-28
$13.97M
10-Q · filed 2020-10-28
$18.55M
derived: sum of 4 quarters · filed 2021-02-25
2019-06-30$4.66M
10-Q · filed 2020-07-29
$9.28M
10-Q · filed 2020-07-29
$13.86M
derived: sum of 3 quarters · filed 2021-02-25
$19.10M
derived: sum of 4 quarters · filed 2021-02-25
2019-03-31$4.62M
10-Q · filed 2020-04-29
$9.20M
derived: sum of 2 quarters · filed 2021-02-25
$14.44M
derived: sum of 3 quarters · filed 2021-02-25
$20.91M
derived: sum of 4 quarters · filed 2021-02-25
2018-12-31$4.58M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25
$9.82M
derived: sum of 2 quarters · filed 2021-02-25
$16.30M
derived: sum of 3 quarters · filed 2021-02-25
$23.95M
10-K · filed 2021-02-25
2018-09-30$5.24M
10-Q · filed 2019-10-30
$11.72M
derived: sum of 2 quarters · filed 2019-10-30
$19.37M
10-Q · filed 2019-10-30
$27.73M
derived: sum of 4 quarters · filed 2020-02-19
2018-06-30$6.48M
10-Q · filed 2019-07-24
$14.13M
10-Q · filed 2019-07-24
$22.49M
derived: sum of 3 quarters · filed 2020-02-19
$32.75M
derived: sum of 4 quarters · filed 2020-02-19
2018-03-31$7.66M
10-Q · filed 2019-05-01
$16.01M
derived: sum of 2 quarters · filed 2020-02-19
$26.27M
derived: sum of 3 quarters · filed 2020-02-19
$38.48M
derived: sum of 4 quarters · filed 2020-02-19
2017-12-31$8.35M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-19
$18.62M
derived: sum of 2 quarters · filed 2020-02-19
$30.82M
derived: sum of 3 quarters · filed 2020-02-19
$43.60M
10-K · filed 2020-02-19
2017-09-30$10.26M
10-Q · filed 2018-10-31
$22.47M
derived: sum of 2 quarters · filed 2018-10-31
$35.25M
10-Q · filed 2018-10-31
$48.25M
derived: sum of 4 quarters · filed 2019-02-19
2017-06-30$12.20M
10-Q · filed 2018-07-26
$24.98M
10-Q · filed 2018-07-26
$37.98M
derived: sum of 3 quarters · filed 2019-02-19
$51.09M
derived: sum of 4 quarters · filed 2019-02-19
2017-03-31$12.78M
10-Q · filed 2018-05-04
$25.78M
derived: sum of 2 quarters · filed 2019-02-19
$38.88M
derived: sum of 3 quarters · filed 2019-02-19
$52.04M
derived: sum of 4 quarters · filed 2019-02-19
2016-12-31$13.00M
derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-19
$26.10M
derived: sum of 2 quarters · filed 2019-02-19
$39.26M
derived: sum of 3 quarters · filed 2019-02-19
$52.42M
10-K · filed 2019-02-19
2016-09-30$13.10M
10-Q · filed 2017-11-03
$26.26M
derived: sum of 2 quarters · filed 2017-11-03
$39.42M
10-Q · filed 2017-11-03
$52.46M
derived: sum of 4 quarters · filed 2018-02-23
2016-06-30$13.16M
10-Q · filed 2017-08-08
$26.31M
10-Q · filed 2017-08-08
$39.36M
derived: sum of 3 quarters · filed 2018-02-23
$52.42M
derived: sum of 4 quarters · filed 2018-02-23
2016-03-31$13.16M
10-Q · filed 2017-05-05
$26.20M
derived: sum of 2 quarters · filed 2018-02-23
$39.27M
derived: sum of 3 quarters · filed 2018-02-23
$52.25M
derived: sum of 4 quarters · filed 2018-02-23
2015-12-31$13.05M
derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-23
$26.11M
derived: sum of 2 quarters · filed 2018-02-23
$39.10M
derived: sum of 3 quarters · filed 2018-02-23
$51.80M
10-K · filed 2018-02-23
2015-09-30$13.06M
10-Q · filed 2016-11-03
$26.05M
derived: sum of 2 quarters · filed 2016-11-03
$38.76M
10-Q · filed 2016-11-03
$51.32M
derived: sum of 4 quarters · filed 2017-02-28
2015-06-30$12.99M
10-Q · filed 2016-08-04
$25.69M
10-Q · filed 2016-08-04
$38.26M
derived: sum of 3 quarters · filed 2017-02-28
$50.61M
derived: sum of 4 quarters · filed 2017-02-28
2015-03-31$12.71M
10-Q · filed 2016-05-05
$25.27M
derived: sum of 2 quarters · filed 2017-02-28
$37.63M
derived: sum of 3 quarters · filed 2017-02-28
$47.95M
derived: sum of 4 quarters · filed 2017-02-28
2014-12-31$12.57M
derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-28
$24.92M
derived: sum of 2 quarters · filed 2017-02-28
$35.25M
derived: sum of 3 quarters · filed 2017-02-28
$36.89M
10-K · filed 2017-02-28
2014-09-30$12.36M
10-Q · filed 2015-11-05
$22.68M
derived: sum of 2 quarters · filed 2015-11-05
$24.33M
10-Q · filed 2015-11-05
$26.01M
derived: sum of 4 quarters · filed 2016-02-24
2014-06-30$10.33M
10-Q · filed 2015-08-06
$11.97M
10-Q · filed 2015-08-06
$13.66M
derived: sum of 3 quarters · filed 2016-02-24
$15.56M
derived: sum of 4 quarters · filed 2016-02-24
2014-03-31$1.64M
10-Q · filed 2015-05-08
$3.33M
derived: sum of 2 quarters · filed 2016-02-24
$5.23M
derived: sum of 3 quarters · filed 2016-02-24
$8.26M
derived: sum of 4 quarters · filed 2016-02-24
2013-12-31$1.69M
derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-24
$3.59M
derived: sum of 2 quarters · filed 2016-02-24
$6.61M
derived: sum of 3 quarters · filed 2016-02-24
$9.35M
10-K · filed 2016-02-24
2013-09-30$1.90M
10-Q · filed 2014-11-04
$4.93M
derived: sum of 2 quarters · filed 2014-11-04
$7.66M
10-Q · filed 2014-11-04
$9.16M
derived: sum of 4 quarters · filed 2015-02-27
2013-06-30$3.02M
10-Q · filed 2014-08-07
$3.02M
10-Q · filed 2013-08-01
$5.76M
10-Q · filed 2014-08-07
$7.26M
derived: sum of 3 quarters · filed 2015-02-27
$8.76M
derived: sum of 4 quarters · filed 2015-02-27
2013-03-31$2.74M
10-Q · filed 2014-05-07
$4.24M
derived: sum of 2 quarters · filed 2015-02-27
$5.74M
derived: sum of 3 quarters · filed 2015-02-27
$7.24M
derived: sum of 4 quarters · filed 2015-02-27
2012-12-31$1.50M
derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-27
$3.00M
derived: sum of 2 quarters · filed 2015-02-27
$4.50M
derived: sum of 3 quarters · filed 2015-02-27
$6.00M
10-K · filed 2015-02-27
2012-09-30$1.50M
10-Q · filed 2013-11-01
$3.00M
derived: sum of 2 quarters · filed 2013-11-01
$4.50M
10-Q · filed 2013-11-01
$6.01M
derived: sum of 4 quarters · filed 2014-03-03
2012-06-30$1.50M
10-Q · filed 2013-08-01
$3.00M
10-Q · filed 2013-08-01
$4.51M
derived: sum of 3 quarters · filed 2014-03-03
$6.01M
derived: sum of 4 quarters · filed 2014-03-03
2012-03-31$1.50M
10-Q · filed 2013-05-01
$3.00M
derived: sum of 2 quarters · filed 2014-03-03
$4.51M
derived: sum of 3 quarters · filed 2014-03-03
$6.02M
derived: sum of 4 quarters · filed 2014-03-03
2011-12-31$1.50M
derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-03
$3.01M
derived: sum of 2 quarters · filed 2014-03-03
$4.51M
derived: sum of 3 quarters · filed 2014-03-03
$6.02M
10-K · filed 2014-03-03
2011-09-30$1.50M
10-Q · filed 2012-10-31
$3.01M
derived: sum of 2 quarters · filed 2012-10-31
$4.52M
10-Q · filed 2012-10-31
$6.03M
derived: sum of 4 quarters · filed 2013-02-26
2011-06-30$1.51M
10-Q · filed 2012-08-01
$3.02M
10-Q · filed 2012-08-01
$4.52M
derived: sum of 3 quarters · filed 2013-02-26
$6.04M
derived: sum of 4 quarters · filed 2013-02-26
2011-03-31$1.51M
10-Q · filed 2012-05-02
$3.02M
derived: sum of 2 quarters · filed 2013-02-26
$4.53M
derived: sum of 3 quarters · filed 2013-02-26
$6.04M
derived: sum of 4 quarters · filed 2013-02-26
2010-12-31$1.51M
derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-26
$3.02M
derived: sum of 2 quarters · filed 2013-02-26
$4.53M
derived: sum of 3 quarters · filed 2013-02-26
$6.04M
10-K · filed 2013-02-26
2010-09-30$1.51M
10-Q · filed 2011-11-02
$3.02M
derived: sum of 2 quarters · filed 2011-11-02
$4.54M
10-Q · filed 2011-11-02
2010-06-30$1.51M
10-Q · filed 2011-08-03
$3.02M
10-Q · filed 2011-08-03
2009-12-31$6.05M
10-K · filed 2012-02-27

Similar stocks

Stock NameCountryMarket CapPE Ratio
ArriVent BioPharma, Inc. (AVBP)United States$1.485B-10.25
Ultragenyx Pharmaceutical Inc. (RARE)United States$1.456B-5.62
OMEROS CORP (OMER)United States$1.456B5.50
ANAPTYSBIO, INC (ANAB)United States$1.546B-60.20
Kailera Therapeutics, Inc. (KLRA)United States$1.552B
Syndax Pharmaceuticals Inc (SNDX)United States$1.606B-8.82
Oric Pharmaceuticals, Inc. (ORIC)United States$1.367B-8.00
Rapport Therapeutics, Inc. (RAPP)United States$1.623B-14.56
Stoke Therapeutics, Inc. (STOK)United States$1.630B-9.82
Xeris Biopharma Holdings, Inc. (XERS)United States$1.632B-80.10